Vittorio Martinelli

List of Publications by Year
in descending order

89 papers	5,133 citations	168829 31 h-index	100535 70 g-index
90 all docs	90 docs citations	90 times ranked	5332 citing authors

#	Article	IF	Citations
1	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.5	31
2	Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?. European Review for Medical and Pharmacological Sciences, 2022, 26, 935-946.	0.5	1
3	MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD. Journal of Neurology, Neurosurgery and Psychiatry, 2022, , jnnp-2022-328956.	0.9	1
4	CSF extracellular vesicles and risk of disease activity after a first demyelinating event. Multiple Sclerosis Journal, 2021, 27, 1606-1610.	1.4	9
5	‹i›MYD88‹/i› L265P mutation and interleukinâ€10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. British Journal of Haematology, 2021, 193, 497-505.	1.2	41
6	Corticoâ€subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. European Journal of Neurology, 2021, 28, 2249-2258.	1.7	7
7	Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	19
8	Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report. Neurological Sciences, 2021, 42, 3969-3971.	0.9	3
9	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after SARS-CoV-2 pneumonia. Neurological Sciences, 2021, 42, 4373-4375.	0.9	4
10	Diagnosing autoimmune encephalitis in a real-world single-centre setting. Journal of Neurology, 2020, 267, 449-460.	1.8	28
11	Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability. Radiology, 2020, 297, 154-163.	3.6	13
12	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Annals of Neurology, 2020, 88, 1034-1042.	2.8	89
13	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. Journal of the Neurological Sciences, 2020, 417, 117064.	0.3	1
14	Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review. Journal of Neurology, 2020, 267, 2462-2468.	1.8	15
15	In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. Scientific Reports, 2019, 9, 10371.	1.6	31
16	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 33, 75-77.	0.9	13
17	Reply to â€œSerum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathyâ€. Annals of Neurology, 2019, 86, 324-324.	2.8	4
18	Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. Clinical Therapeutics, 2019, 41, 249-260.e18.	1.1	17

#	Article	IF	Citations
19	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumabâ€treated multiple sclerosis patients. Annals of Neurology, 2019, 85, 606-610.	2.8	30
20	Assessing seasonal dynamics of Guillain-BarrÃ© syndrome with search engine query data. Neurological Sciences, 2019, 40, 1015-1018.	0.9	3
21	Brain and cord imaging features in neuromyelitis optica spectrum disorders. Annals of Neurology, 2019, 85, 371-384.	2.8	66
22	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology, 2019, 92, e733-e741.	1.5	57
23	Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2019, 27, 403-405.	0.9	18
24	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. Multiple Sclerosis and Related Disorders, 2019, 28, 57-59.	0.9	1
25	Cognitive reserve, cognition, and regional brain damage in MS: A 2â€‰-year longitudinal study. Multiple Sclerosis Journal, 2019, 25, 372-381.	1.4	40
26	The CSF p-tau181/AÎ²42 Ratio Offers a Good Accuracy â€œIn Vivoâ€•in the Differential Diagnosis of Alzheimerâ€™s Dementia. Current Alzheimer Research, 2019, 16, 587-595.	0.7	17
27	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.5	102
28	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.5	74
29	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. Journal of Neurology, 2018, 265, 896-905.	1.8	12
30	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	4.9	98
31	Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Annals of Neurology, 2018, 83, 283-294.	2.8	160
32	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. Multiple Sclerosis Journal, 2018, 24, 459-471.	1.4	105
33	Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. Neurological Sciences, 2018, 39, 373-376.	0.9	11
34	Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2018, 24, 69-71.	0.9	20
35	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. Multiple Sclerosis and Related Disorders, 2018, 25, 73-76.	0.9	4
36	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. Acta Neurologica Scandinavica, 2018, 138, 447-453.	1.0	4

#	Article	IF	Citations
37	Digital epidemiology confirms a latitude gradient of MS in France. Multiple Sclerosis and Related Disorders, 2018, 20, 129-131.	0.9	6
38	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. Journal of the Neurological Sciences, 2018, 384, 58-60.	0.3	2
39	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. Multiple Sclerosis Journal, 2017, 23, 577-587.	1.4	26
40	Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology, 2017, 88, 1439-1444.	1.5	85
41	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. Multiple Sclerosis Journal, 2017, 23, 1918-1928.	1.4	13
42	Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case. Multiple Sclerosis Journal, 2017, 23, 1558-1561.	1.4	4
43	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. Acta Neurologica Scandinavica, 2017, 136, 454-461.	1.0	18
44	Moyamoya disease mimicking the first attack of multiple sclerosis. Journal of Neurology, 2017, 264, 1005-1007.	1.8	2
45	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain, 2017, 140, 2814-2819.	3.7	51
46	High frequency of intestinal T _H 17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Science Advances, 2017, 3, e1700492.	4.7	228
47	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. Journal of the Neurological Sciences, 2017, 383, 166-168.	0.3	29
48	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. Neurological Sciences, 2017, 38, 361-364.	0.9	8
49	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. Brain Imaging and Behavior, 2017, 11, 1238-1247.	1.1	5
50	Treatment Challenges of a Primary Vertebral Artery Aneurysm Causing Recurrent Ischemic Strokes. Case Reports in Neurological Medicine, 2017, 2017, 1-3.	0.3	9
51	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	0.9	90
52	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. Viruses, 2016, 8, 128.	1.5	2
53	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. Multiple Sclerosis International, 2016, 2016, 1-9.	0.4	18
54	Progressive ataxia in a natalizumabâ€treated multiple sclerosis patient: the dark side of JC virus infection. European Journal of Neurology, 2016, 23, e39-40.	1.7	2

#	Article	IF	Citations
55	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. Journal of the Neurological Sciences, 2016, 361, 184-186.	0.3	2
56	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. Human Brain Mapping, 2016, 37, 2293-2304.	1.9	29
57	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Multiple Sclerosis Journal, 2016, 22, 1506-1508.	1.4	41
58	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Multiple Sclerosis Journal, 2016, 22, 1315-1326.	1.4	62
59	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurological Sciences, 2016, 37, 613-622.	0.9	14
60	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Multiple Sclerosis Journal, 2016, 22, 511-519.	1.4	76
61	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	0.8	31
62	The Communication of Multiple Sclerosis Diagnosis: The Patientsâ€™ Perspective. Multiple Sclerosis International, 2015, 2015, 1-7.	0.4	7
63	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
64	A pharmacogenetic study implicates <scp>SLC9a9</scp> in multiple sclerosis disease activity. Annals of Neurology, 2015, 78, 115-127.	2.8	39
65	Thrombolysis with rt-PA for an ischemic stroke in boy treated with Fontan operation. Journal of Pediatric Neurology, 2015, 09, 497-500.	0.0	0
66	Validation of 1â€year predictive score of longâ€term response to interferonâ€Î² in everyday clinical practice multiple sclerosis patients. European Journal of Neurology, 2015, 22, 973-980.	1.7	16
67	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. Journal of Neuroimmunology, 2015, 289, 62-67.	1.1	20
68	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	0.8	99
69	Opinion & Special Articles: Professionalism in neurology. Neurology, 2014, 83, e12-5.	1.5	4
70	Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Multiple Sclerosis Journal, 2014, 20, 147-155.	1.4	94
71	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 862-870.	1.4	11
72	Clinical and <scp>MRI</scp> predictors of response to interferonâ€beta and glatiramer acetate in relapsingâ€“remitting multiple sclerosis patients. European Journal of Neurology, 2013, 20, 1060-1067.	1.7	27

#	Article	IF	Citations
73	Disclosing the diagnosis of multiple sclerosis: The Profile Project. Journal of Neurology, 2012, 259, 2605-2610.	1.8	8
74	Sturge-Weber syndrome with an unusual onset in the sixth decade: a case report. Neurological Sciences, 2012, 33, 949-950.	0.9	5
75	Anxiety and depression in multiple sclerosis patients around diagnosis. Journal of the Neurological Sciences, 2011, 307, 86-91.	0.3	105
76	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 2011, 77, 1887-1895.	1.5	68
77	Comparative study of mitoxantrone efficacy profile in patients with relapsingâ€"remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1490-1499.	1.4	26
78	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. Multiple Sclerosis Journal, 2010, 16, 100-111.	1.4	50
79	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology, 2009, 73, 1842-1848.	1.5	74
80	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 374, 1503-1511.	6.3	551
81	Communicating the diagnosis of multiple sclerosis - a qualitative study. Multiple Sclerosis Journal, 2007, 13, 763-769.	1.4	77
82	Combination therapy. Neurological Sciences, 2006, 27, s350-s354.	0.9	11
83	Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1030-1035.	0.9	130
84	Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurology, The, 2005, 4, 618-626.	4.9	235
85	Induction versus escalation therapy. Neurological Sciences, 2005, 26, s193-s199.	0.9	7
86	Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurological Sciences, 2004, 25, s350-s355.	0.9	71
87	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, The, 2001, 357, 1576-1582.	6.3	1,025
88	EEG correlates of cognitive impairment in MS. Italian Journal of Neurological Sciences, 1998, 19, S413-S417.	0.1	4
89	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. Journal of Neurology, 1996, 243, 502-505.	1.8	115